MétaCan
Menu
Back to cohort
Record W2766632403

A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease

2017· article· en· W2766632403 on OpenAlex
Andrew McGarry, Michael McDermott, Karl Kieburtz, Elisabeth A. de Blieck, F Béal, Karen Marder, Christopher A. Ross, Ira Shoulson, Peter Gibert, William Mallonee, Mark Guttman, Joanne Wojcieszek, Rajeev Kumar, Mark S. LeDoux, Mary Jenkins, H. Diana Rosas, Martha Nance, Kevin Biglan, Peter G. Como, Richard Dubinsky, Kathleen M. Shannon, Padraig O’Suilleabhain, Kelvin L. Chou, Francis O. Walker, W. R. Wayne Martin, Vicki Wheelock, Elizabeth McCusker, Joseph Jankovic, Carlos Singer, Juan Sanchez‐Ramos, B.L. Scott, Oksana Suchowersky, Stewart A. Factor, Donald S. Higgins, Eric Molho, Fredy J. Revilla, John N. Caviness, Joseph H. Friedman, Joel S. Perlmutter, Andrew Feigin, Karen E. Anderson, Ramon L. Rodriguez, Nikolaus R. McFarland, Russell L. Margolis, Eric S. Farbman, Lynn A. Raymond, Valerie Suski, Sandra K. Kostyk, Amy Colcher, Lauren Seeberger, Eric A. Epping, Sherali Esmail, Nancy Díaz, Wai Lun Alan Fung, Alan Diamond, Samuel Frank, Philip Hanna, Neal Hermanowicz, Leon Dure, Merit Cudkowicz

Why this work is in the frame

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

aboutThe title or abstract carries a Canadian signal from the geographic lexicon.
no affNo Canadian affiliation: this work is invisible to an affiliation-only frame.
No Canadian affiliation. An affiliation-only frame, the usual design, would never have seen this work. It is one of the works that make the case for inverting the frame.

Bibliographic record

Venuenot available
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicCoenzyme Q10 studies and effects
Canadian institutionsnot available
Fundersnot available
KeywordsHuntington's diseaseCoenzyme Q10Double blindPlaceboMedicineDiseaseRandomized controlled trialAudiologyInternal medicinePathologyAlternative medicine
DOInot available

Abstract

fetched live from OpenAlex

ObjectiveTo test the hypothesis that chronic treatment of early-stage Huntington disease (HD) with high-dose coenzyme Q10 (CoQ) will slow the progressive functional decline of HD.MethodsWe performed a multicenter randomized, double-blind, placebo-controlled trial. Patients with early-stage HD (n = 609) were enrolled at 48 sites in the United States, Canada, and Australia from 2008 to 2012. Patients were randomized to receive either CoQ 2,400 mg/d or matching placebo, then followed for 60 months. The primary outcome variable was the change from baseline to month 60 in Total Functional Capacity score (for patients who survived) combined with time to death (for patients who died) analyzed using a joint-rank analysis approach.ResultsAn interim analysis for futility revealed a conditional power of <5% for the primary analysis, prompting premature conclusion in July 2014. No statistically significant differences were seen between treatment groups for the primary or secondary outcome measures. CoQ was generally safe and well-tolerated throughout the study.ConclusionsThese data do not justify use of CoQ as a treatment to slow functional decline in HD.Clinicaltrialsgov identifierNCT00608881.Classification of evidenceThis article provides Class I evidence that CoQ does not slow the progressive functional decline of patients with HD.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.008
Threshold uncertainty score0.569

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.018
GPT teacher head0.298
Teacher spread0.280 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Quick stats

Citations28
Published2017
Admission routes1
Has abstractyes

Explore more

Same topicCoenzyme Q10 studies and effectsFrench-language works237,207